Last updated on November 2017

AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND #76431; NSC# 617807)


Brief description of study

AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND #76431; NSC# 617807)

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00557193?term=AALL0631&rank=1

Clinical Study Identifier: TX13364

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Patricia Green

Memorial University Medical Center
Savannah, GA USA
  Connect »